Minnesota Glomerular Disease Program

Front Row from Left to Right: Lama Ghazi, Michelle Hintz, Surabhi Thakar, Charlotte Quinton
Back Row from Left to Right: Rana Leed, Patrick Nachman, Katti Woerner, and Elizabeth Miller

Mission

To provide patients with glomerular disease with expert, individualized care and access to clinical trials.

Covered Diseases

Any glomerular disease, including (but not limited to):

Focal Segmental Glomerulosclerosis (FSGS)
Membranous nephropathy
Minimal change disease
IgA nephropathy
Immune complex mediated diseases
C3 Glomerulopathy
Fibrillary Glomerular Disease
Cryoglobulinemia
Anti-Glomerular Basement Membrane (anti-GBM) Disease
Alport Syndrome
Thin basement membrane disease
Vasculitis
Lupus Nephritis

For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage

Goals

Provide patients with glomerular disease with expert care which is organized, streamlined and efficient.
Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
Provide patients with access to cutting-edge clinical trials.
Facilitate translational research.
Provide a venue for health care providers training in the care of patients with glomerular disease.

Our Team

Physicians

Clinical & Translational Research Team

Joy Bolea RN, MS - Clinical Research Coordinator
Mary McDonald, RN, CCRP - Clinical Research Coordinator
Scott Rajala, CCRP - Clinical Research Coordinator

Ongoing Clinical Trials

FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Phase 2a Trial

A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease

Principal Investigator
Patrick Nachman, MD

Co-Investigators
Surabhi Thakar, MD
Katti Woerner, MD

Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

IGA NEPHROPATHY

Phase 3 Trial

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)

Principal Investigator
Patrick H. Nachman, MD

Co-Investigators
Surabhi Thakar, MD

Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu

CLINICAL TRIAL

Phase 3 Trial

Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy

Principal Investigator
Sahar Koubar, MBBS
Co-Investigators
Nattawat Klomjit, MD
Patrick H. Nachman, MD

Study Coordinators
Joy Bolea, RN, MS
jbolea@umn.edu

CLINICAL TRIAL